[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsedrefractory-diffuse-large-b-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsedrefractory-diffuse-large-b-cell-lymphoma":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,76,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100624422","phase-3-a-phase-iii-study-of-hmpl-760-plus-r-gemox-vs-placebo-plus-r-gemox-in-relapsedrefractory-dlbcl-100624422",false,"NCT07409428","A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed\u002FRefractory DLBCL","A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma (DLBCL)","Inclusion Criteria:\n\n1. Sign the ICF and be able to follow the requirements of study protocol;\n2. Age ≥18 years;\n3. ECOG performance status score between 0 and 2;\n4. Histopathologically confirmed diagnosis of DLBCL;\n5. The investigator judges that the patient's current condition requires further treatment;\n6. Patients should have at least one bi-dimensionally measurable lesion;\n7. Expected survival is more than 12 weeks;\n\nExclusion Criteria:\n\n1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;\n2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;\n3. Organ insufficiency;\n4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);\n5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;\n6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);\n7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);\n8. Clinically significant active infection;","ALL","18 Years",{"count":19,"type":20},240,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R\u002FR DLBCL.",[26],"Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[28,29,30],"HMPL-760","R-GemOx (rituximab, gemcitabine, and oxaliplatin)","R\u002FR DLBCL","RECRUITING","2026-03-27",{"date":34,"type":35},"2026-04-01","ACTUAL",{"date":37,"type":35},"2026-03-20",{"date":39,"type":20},"2028-12-30",{"name":41,"class":42},"Hutchmed","INDUSTRY",41,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100627670","phase-2-low-dose-epcoritamab-plus-gemox-in-rr-dlbcl-100627670","NCT07451652","Low Dose Epcoritamab Plus GemOx in R\u002FR DLBCL","Low Dose Epcoritamab Plus Gemcitabine\u002FOxaliplatin in Treatment of Transplant Eligible Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma","Inclusion Criteria:\n\n* Subjects with relapsed\u002Frefractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant\n* ECOG 0-2\n* Women of reproductive age who agree on getting a contraceptive method\n* Subjects who fulfill Lugano´s criteria for disease activity\n* Subjects who voluntarily accept to participate in this study\n\nExclusion Criteria:\n\n* Active bacterial, viral or fungal infection\n* Subjects who have already received an autologous o allogeneic stem cell transplantation\n* Subjects with other active neoplasias\n* Subjects with end-stage failure","65 Years",{"count":53,"type":20},10,[55],"PHASE2","In this study, researchers are looking to determine whether Gemcitabine\u002FOxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed\u002Frefractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.",[58],"Relapsed\u002FRefractory Diffuse Large B Cell Lymphoma",[60,61,62,63,64,65],"relapsed\u002Frefractory diffuse large B cell lymphoma","epcoritamab","GemOx","gemcitabine","oxaliplatin","autologous stem cell transplant","2026-03-26",{"date":34,"type":35},{"date":69,"type":35},"2026-03-17",{"date":71,"type":20},"2027-09",{"name":73,"class":74},"Hospital Universitario Dr. Jose E. Gonzalez","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":75},"100585411","phase-1-safety-and-efficacy-of-early-second-infusion-of-axi-cel-based-on-ctdna-for-rr-large-b---cell-lymphoma-100585411","NCT06902012","Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R\u002FR Large B - Cell Lymphoma","A Prospective, Single - Arm Clinical Study on the Safety and Efficacy of Early Second Infusion of CD19 CAR - T Based on ctDNA Monitoring in the Treatment of Relapsed\u002FRefractory Large B - Cell Lymphoma","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of gender.\n2. Life expectancy \\>12 weeks.\n3. ECOG performance status 0-2.\n4. Histologically or cytologically confirmed B-cell non-Hodgkin lymphoma per WHO 2016 classification, including:\n\n   Diffuse large B-cell lymphoma (DLBCL) Primary mediastinal large B-cell lymphoma (PMBCL) Transformed follicular lymphoma (TFL) High-grade B-cell lymphoma (HGBCL).\n5. Relapsed\u002Frefractory disease, defined as:\n\n   ≥1 prior relapse, Failure to achieve partial response (PR) after 2-3 cycles of first-line therapy, Failure to achieve complete response (CR) after 4-6 cycles of first-line therapy, Primary refractory disease, Secondary refractory disease, Disease progression following last line of therapy.\n6. Adequate venous access for leukapheresis, with:\n\n   Hemoglobin ≥80 g\u002FL, Absolute neutrophil count ≥1.0 ×10⁹\u002FL, Platelet count ≥75 ×10⁹\u002FL, OR parameters not meeting above thresholds but deemed acceptable for mononuclear cell collection per investigator's judgment.\n7. ≥1 measurable lesion per Lugano 2014 response criteria.\n8. Organ function requirements:\n\n   Renal: Serum creatinine ≤2×ULN OR creatinine clearance ≥40 mL\u002Fmin (Cockcroft-Gault formula).\n\n   Cardiopulmonary:\n\n   Left ventricular ejection fraction (LVEF) \\>50%, Baseline oxygen saturation \\>92% on room air.\n\n   Hepatic:\n\n   Total bilirubin ≤2×ULN (≤5×ULN in Gilbert syndrome), ALT\u002FAST ≤3×ULN (≤5×ULN in patients with hepatic involvement).\n9. Negative serum pregnancy test for women of childbearing potential (WOCBP). Postmenopausal (≥2 years since last menses) or surgically sterilized women are exempt.\n10. Within 60 days post-axi-cel:\n\nPersistent ctDNA(+) or ctDNA(-→+) under CR or PET\u002FCT-confirmed PR\n\nExclusion Criteria:\n\n1. History of malignancies other than DLBCL, PMBCL, TFL, or HGBCL within 5 years prior to screening, except:\n\n   Adequately treated carcinoma in situ of the cervix, Basal cell or squamous cell carcinoma of the skin, Localized prostate cancer after definitive resection, Ductal carcinoma in situ of the breast after curative surgery, Thyroid cancer after radical treatment.\n2. Unstable systemic diseases, including but not limited to:\n\n   Active infections (excluding localized infections), Unstable angina, Cerebrovascular accident or transient ischemic attack (within 6 months prior to screening), Myocardial infarction (within 6 months prior to screening), Congestive heart failure (NYHA Class ≥III), Severe arrhythmia requiring pharmacologic management, Hepatic, renal, or metabolic disorders.\n3. Conditions affecting informed consent or protocol compliance:\n\n   Physical or psychological disorders impairing the ability to provide written informed consent, Inability or unwillingness to comply with study requirements.\n4. Grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) following prior axi-cel therapy.\n5. Active, uncontrolled serious infections.\n6. Uncontrolled active comorbidities that preclude study participation.\n7. Other conditions deemed by the investigator to confer unacceptable risk or render the patient ineligible.",{"count":84,"type":20},15,[86,55],"PHASE1","The goal of this clinical trial is to evaluate the efficacy and safety of early secondary infusion of CD19 CAR T-cell therapy in adults with relapsed\u002Frefractory diffuse large B-cell lymphoma (DLBCL), guided by ctDNA monitoring. The main questions it aims to answer are:\n\n1. Efficacy: Does early secondary CAR-T infusion improve the 3-month complete remission (CR) rate and long-term survival outcomes (e.g., 1-year PFS, OS)?\n2. Safety: What are the adverse events associated with secondary CAR-T infusion, such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity (ICANS), and infections?\n\nThis is a single-arm, single-center, prospective study. All participants will receive:\n\n* Leukapheresis to collect T cells for CAR-T manufacturing.\n* Preconditioning chemotherapy (fludarabine and cyclophosphamide) to prepare the body for CAR-T infusion.\n* Two CD19 CAR-T infusions: The first infusion (2×10⁶ cells\u002Fkg) followed by a second infusion (same dose) if ctDNA remains positive when PET\u002FCT shows CR or PET\u002FCT shows PR within 60 days post-first infusion.\n\nParticipants will undergo:\n\n* Frequent hospital monitoring for ≥14 days post-infusion to manage potential toxicities.\n* Regular follow-ups (e.g., blood tests, ctDNA analysis, PET\u002FCT scans) at scheduled intervals up to 12 months.\n* Continuous safety assessments, including CRS grading, neurological evaluations, and infection monitoring.",[89],"Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma",[91,92,93],"CAR-T","LYMPHOMA","SENCOND INFUSION","2025-03-24",{"date":96,"type":35},"2025-03-30",{"date":98,"type":20},"2027-02",{"date":100,"type":20},"2028-08",{"name":102,"class":74},"Zhujiang Hospital",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":75},"100576973","phase-3-study-comparing-bebt-908-combined-with-r-to-soc-for-the-treatment-of-relapsedrefractory-diffuse-large-b-cell-lymphoma-100576973","NCT06792253","Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma","Phase Ⅲ Clinical Trial Comparing BEBT-908 Combined With Rituximab (R) to Standard of Care for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n1. The subject has been fully informed and is willing to sign the Informed Consent Form (ICF).\n2. Age is ≥18 years and ≤75 years, both men and women are eligible.\n3. Pathologically diagnosed as diffuse large B-cell lymphoma according to the 2022 World Health Organization classification, confirmed by central pathology review (Patients who relapse after more than one year need to undergo tissue biopsy again to confirm the pathological diagnosis.).\n4. Measurable lesions \\[The criteria for measurable lesions are: the longest diameter of lymph node lesions measured by enhanced Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) is greater than 15 mm, and the longest diameter of extranodal lesions is greater than 10 mm.\\] assessed by Positron Emission Tomography\u002FComputed Tomography (PET-CT) and Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) according to the Lugano 2014 criteria .\n5. Must have relapsed or refractory diffuse large B-cell lymphoma after at least one systemic therapy \\[Salvage chemotherapy and immunotherapy after stem cell transplantation will be considered as first-line systemic treatment; maintenance therapy will not be counted as a separate line of systemic treatment; local radiotherapy for diffuse large B-cell lymphoma (DLBCL) aimed at cure will not be counted as first-line systemic treatment; patients who do not achieve PR after four cycles of first-line treatment are eligible for the study; patients who do not achieve PR after two cycles of second-line or higher treatment are eligible for the study. Primary refractory DLBCL patients are defined as those who have no response during first-line treatment or relapse within six months after the end of treatment, and they will be allowed to participate in the study. Patients who relapse within 12 months after stem cell transplantation are also eligible for inclusion. Refractory DLBCL patients are those who do not achieve response after adequate front-line treatment (at least four cycles of first-line chemotherapy, or at least two cycles of subsequent treatment), or who progress during previous first-line treatment, or who progress within six months (less than six months) after achieving response to previous adequate front-line treatment, or who relapse within 12 months after achieving response to stem cell transplantation. Relapsed DLBCL patients are those who relapse six months or more after achieving response to previous adequate front-line treatment, or who relapse 12 months or more after achieving response to stem cell transplantation.\\], and at least one systemic therapy must include CD20 antibody.\n6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n7. Expected survival \\>12 weeks.\n8. Organ function levels must meet the following requirements:\n\nPeripheral blood:\n\n1. Absolute neutrophil count (ANC) ≥1.0×10\\^9\u002FL;\n2. Hemoglobin (HGB) ≥80g\u002FL;\n3. Platelet count (PLT) ≥100×10\\^9\u002FL;\n\nLiver and kidney function:\n\n1. Serum total bilirubin ≤1.5×Upper Limit of Normal (ULN) (for patients with Gilbert syndrome, total bilirubin \\\u003C3.0×ULN with direct bilirubin within normal range);\n2. Serum creatinine \\\u003C1.5×ULN;\n3. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) ≤2.5×ULN (≤5×ULN if there is liver involvement).\n\nExclusion Criteria:\n\n1. Known severe allergy to the study drug or any of its excipients;\n2. Due to the potential genotoxicity, mutagenicity, and teratogenicity of the study drug, the following subjects should be excluded:\n\n   1. Men and women who have not undergone in vitro preservation of sperm or oocytes and plan to have children within 5 years, unless subsequent studies confirm reproductive safety;\n   2. Pregnant or breastfeeding women;\n3. Primary central nervous system lymphoma;\n4. DLBCL with active central nervous system brain metastases or meningeal involvement at the time of screening;\n5. Other active malignant tumors that require treatment and may interfere with the study.\n6. Treatment history before the trial:\n\n   1. Received other small molecule targeted drug therapy within 2 weeks before enrollment;\n   2. Previously received BEBT-908 or R-ICE and R-GemOx therapy before enrollment;\n   3. Underwent autologous hematopoietic stem cell transplantation within 3 months before enrollment;\n   4. Received radiotherapy that affects the evaluation of the efficacy of this study within 3 months before enrollment, or local supportive radiotherapy that affects the subject's bone marrow function;\n   5. Underwent myelosuppressive chemotherapy or biological therapy within 3 weeks before enrollment;\n   6. Used traditional Chinese medicine and patent medicine with antitumor effects within 2 weeks before enrollment;\n   7. Underwent major surgery (Referring to the Level 3 and Level 4 surgeries as stipulated in the \"Administrative Measures for the Clinical Application of Medical Technologies\" implemented on May 1, 2009.) other than tumor biopsy within 4 weeks before enrollment, or the side effects of the surgery have not yet stabilized;\n   8. Received any hematopoietic cell colony-stimulating factor therapy (such as granulocyte colony-stimulating factor G-CSF, granulocyte-macrophage colony-stimulating factor GM-CSF) or thrombopoietin TPO therapy (Subjects who have started receiving erythropoiesis-stimulating agents or darbepoetin within 2 weeks prior to enrollment are eligible for inclusion.) within 2 weeks before enrollment;\n   9. Received prednisone \\>10mg per day (or other equivalent doses of glucocorticoids) within 7 days before enrollment \\[If used for the treatment of diseases other than lymphoma, such as rheumatoid arthritis, polymyalgia rheumatica, adrenal insufficiency, or asthma, subjects may receive a stable dose of up to 10 mg per day of prednisone (or an equivalent dose of other glucocorticoids).\\];\n   10. Underwent chimeric antigen receptor T cell immunotherapy (CAR-T therapy) within 3 months before enrollment.\n7. After the previous treatment (chemotherapy or biological therapy), there are persistent Grade 2 or higher \\[Common Terminology Criteria for Adverse Events (CTCAE) V5.0 criteria\\] toxicities that have not stabilized at the time of enrollment (alopecia excluded);\n8. There is an active clinical severe infection of Grade 2 or higher (CTCAE V5.0 criteria);\n9. Co-morbid conditions:\n\n   1. Poorly controlled diabetes mellitus \\[with a random blood glucose level ≥11.1 mmol\u002FL or Glycosylated Hemoglobin, Type A1C (HbA1c) ≥8.5% despite hypoglycemic treatment\\];\n   2. Severe pulmonary disease (CTCAE V5.0 Grade III-IV);\n   3. Severe cardiac disease \\[Including any of the following: left ventricular ejection fraction (LVEF) \\\u003C50% detected by cardiac radionuclide scan \\[Multigated Acquisition (MUGA)\\] or echocardiogram (ECHO); Fridericia-corrected QT value (QTcF interval) \\>450ms for males and \\> 470ms for females (QTcF formula); unstable angina; symptomatic pericarditis; myocardial infarction within the past 6 months with persistent elevation of cardiac enzymes or persistent regional left ventricular wall abnormalities recorded during LVEF measurement; history of congestive heart failure (New York Heart Association Class III-IV), or history of cardiomyopathy.\\].\n   4. Significant renal or hepatic dysfunction;\n   5. Uncontrolled active hepatitis B, hepatitis C, syphilis (individuals with both specific and non-specific syphilis antibodies positive), and active Epstein-Barr virus infection \\[The following active infections with clinical significance, including hepatitis B (HBV), hepatitis C (HCV), and syphilis. Active hepatitis B is defined as: hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg) or hepatitis B core antibody positive, and HBV DNA ≥ 2000 IU\u002Fml (approximately equal to 10\\^4 copies\u002Fml), hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg) positive, HBV DNA \\\u003C 2000 IU\u002Fml, according to the requirements of infectious disease control, the subject should continue to take antiviral drug treatment); active hepatitis C is defined as: HCV RNA above the upper limit of detection; positive syphilis spirochete antibody test, should be tested for non-specific syphilis spirochete antibodies \\[Rapid Plasma Reagin Test (PRP) or Toluidine Red Unheated Serum Test (TRUST)\\], the latter is negative and the subject is judged by the researcher to have been infected with syphilis in the past but has been cured can be included; current EB virus infection refers to EB virus serological detection of Epstein-Barr Virus Capsid Antigen Immunoglobulin M (VCA-IgM), Epstein-Barr Virus Early Antigen Immunoglobulin G (EA-IgG) positive or EB virus DNA test positive.\\];\n   6. Known positive for human immunodeficiency virus (HIV);\n   7. History of mental illness, family history of mental illness, or mood disorders as judged by the investigator or psychiatrist \\[Including a medical history of depressive episodes, bipolar disorder (Type I or II), obsessive-compulsive disorder, schizophrenia, suicide attempts or suicidal ideation, or thoughts of killing (immediate risk of harming others), and anxiety levels above Grade 3.\\], and deemed unsuitable for enrollment by the investigator;\n   8. Need for concomitant anticoagulant or antiplatelet therapy during the study period;\n   9. Uncontrolled hypertension (systolic blood pressure ≥180 mmHg and\u002For diastolic blood pressure ≥110 mmHg);\n   10. Severe internal medical conditions with a risk of major bleeding or a history of major bleeding.\n10. Concurrent use of drugs that may cause QT interval prolongation or torsades de pointes;\n11. Within 4 weeks prior to enrollment, currently receiving or requiring treatment with strong inhibitors or inducers of cytochrome P450 (CYP) 3A4 isoenzyme after enrollment (Within 4 weeks prior to enrollment and during the study period, subjects must not receive treatment with strong inhibitors or inducers of the cytochrome P450 (CYP) 3A4 isoenzyme. However, concurrent treatment with moderate or weak CYP3A4 inhibitors is permitted.);\n12. Within 4 weeks prior to enrollment, participated in other clinical trials and used investigational drugs;\n13. Any unstable condition or situation that may jeopardize the subject's safety and compliance with the study as judged by the investigator;\n14. Subjects deemed unsuitable for treatment with this protocol by the investigator.","75 Years",{"count":112,"type":20},416,[23],"This is a multicenter, randomized, controlled, open-label Phase III clinical trial, aimed at evaluating the efficacy and safety of BEBT-908 combined with rituximab (R) compared to investigator-selected standard chemotherapy regimens \\[Standard of Care (SOC)\\] \\[i.e., rituximab-gemcitabine-oxaliplatin (R-GemOx) or rituximab-ifosfamide-carboplatin-etoposide (R-ICE)\\] for the treatment of relapsed\u002Frefractory diffuse large B-cell lymphoma (r\u002Fr DLBCL).",[26],[117,118,119],"BEBT-908","Efficacy","Safety","2025-01-20",{"date":122,"type":35},"2025-01-24",{"date":124,"type":35},"2025-01-06",{"date":126,"type":20},"2029-06-30",{"name":128,"class":42},"BeBetter Med Inc"]